PIK3CA and breast cancer: Moreover, clinical studies on new combinations of the PI3K isoform-specific inhibitors with ET, chemotherapy, CDK 4/6 inhibitors, immune checkpoint inhibitors, or novel target agents are still ongoing and could enhance the clinical benefit due to the possible synergistic action of an innovative treatment tailored to the specific BC subtypes and driven by PIK3CA aberrations.